201 related articles for article (PubMed ID: 27052123)
1. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
[TBL] [Abstract][Full Text] [Related]
2. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
[TBL] [Abstract][Full Text] [Related]
3. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Takase T; Nakamura A; Miyoshi H; Yamamoto C; Atsumi T
Endocr J; 2017 Mar; 64(3):363-367. PubMed ID: 27980239
[TBL] [Abstract][Full Text] [Related]
5. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
Tosaki T; Kamiya H; Himeno T; Kato Y; Kondo M; Toyota K; Nishida T; Shiroma M; Tsubonaka K; Asai H; Moribe M; Nakaya Y; Nakamura J
Intern Med; 2017; 56(6):597-604. PubMed ID: 28321056
[TBL] [Abstract][Full Text] [Related]
10. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
11. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sasaki T; Sugawara M; Fukuda M
J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
[TBL] [Abstract][Full Text] [Related]
15. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
[TBL] [Abstract][Full Text] [Related]
16. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
18. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Tsurutani Y; Nakai K; Inoue K; Azuma K; Mukai S; Maruyama S; Iizuka T; Matsuzawa Y; Saito J; Omura M; Nishikawa T
Diabetes Obes Metab; 2018 Nov; 20(11):2675-2679. PubMed ID: 29893003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]